Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells

Lapatinib, a small molecule ErbB2/EGFR inhibitor, is FDA-approved for the treatment of metastatic ErbB2-overexpressing breast cancer; however, lapatinib resistance is an emerging clinical challenge. Understanding the molecular mechanisms of lapatinib-mediated anti-cancer activities and identifying r...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Zhao, Ming, Howard, Erin W., Parris, Amanda B., Guo, Zhiying, Zhao, Qingxia, Ma, Zhikun, Xing, Ying, Liu, Bolin, Edgerton, Susan M., Thor, Ann D., Yang, Xiaohe
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2017
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5601698/
https://ncbi.nlm.nih.gov/pubmed/28938602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19375
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia